Grace Therapeutics grants 54,690 options to CMO
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27. They vest quarterly over three years, with 1/12 vesting immediately and the remaining 11/12 in equal quarterly installments, subject to continuous service.
Insider Trade Summary
Grant/Award: 54,690 shares
Grant/Award
1 txn
Insider
Macdonald R. Loch
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 54,690 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 54,690 contracts (Direct)
Footnotes (1)
- F1. These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.
Key Figures
Stock options granted: 54,690 options
Exercise price: $2.12 per share
Underlying common shares: 54,690 shares
+3 more
6 metrics
Stock options granted
54,690 options
Grant to Chief Medical Officer on 2026-08-28
Exercise price
$2.12 per share
Exercise price for the 54,690 stock options
Underlying common shares
54,690 shares
Shares issuable upon exercise of the options
Options outstanding after transaction
54,690 options
Total derivative holdings reported for this award following grant
Option expiration date
2036-08-27
Expiration for the granted stock options
Vesting schedule
1/12 at grant; 11/12 over next 11 quarters
Quarterly vesting over a three-year period, subject to continuous service
Key Terms
Stock Option (Right to Buy), exercise price, vesting, continuous service
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "2.1200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"These options vest quarterly in substantially equal installments over a three-year period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service as of each vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did GRCE report for Macdonald R. Loch?
Grace Therapeutics reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28, exercisable for an equal number of common shares at an exercise price of $2.12 per share, expiring on 2036-08-27.
What is the exercise price of the new stock options granted at GRCE?
The stock options granted to Macdonald R. Loch have an exercise price of $2.12 per share. Each option represents the right to buy one share of Grace Therapeutics common stock at this price until the options expire on 2036-08-27.
How many stock options did GRCE grant to its Chief Medical Officer?
Grace Therapeutics granted its Chief Medical Officer, Macdonald R. Loch, 54,690 stock options, representing the right to buy 54,690 shares of common stock. Following this grant, his reported derivative holdings in this award total 54,690 options.
What is the vesting schedule for the GRCE stock options granted to Macdonald R. Loch?
The 54,690 options vest over three years: the first 1/12 vests immediately on the grant date, and the remaining 11/12 vest in substantially equal quarterly installments over the next 11 quarters, subject to Macdonald R. Loch’s continuous service on each vesting date.
When do the newly granted GRCE stock options expire?
The stock options granted to Macdonald R. Loch expire on 2036-08-27. Until that date, and subject to vesting conditions, each option allows him to purchase one share of Grace Therapeutics common stock at an exercise price of $2.12 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
